Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) – Pipeline Review, H1 2019 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Integrin
Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or
CD49d or ITGA4) – Pipeline Review, H1 2019” drug pipelines has
been added to ResearchAndMarkets.com’s offering.

Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit
Alpha or CD49d or ITGA4) pipeline Target constitutes close to 14
molecules. The molecules developed by companies in Pre-Registration,
Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1,
4, 1, 3 and 4 respectively.

Report covers products from therapy areas Gastrointestinal, Central
Nervous System, Immunology, Infectious Disease, Oncology, Ophthalmology,
Cardiovascular, Genetic Disorders, Respiratory and Undisclosed which
include indications Inflammatory Bowel Disease, Ulcerative Colitis,
Graft Versus Host Disease (GVHD), Acute Myelocytic Leukemia (AML, Acute
Myeloblastic Leukemia), Age Related Macular Degeneration, Asthma,
Autoimmune Disorders, Crohn’s Disease (Regional Enteritis), Duchenne
Muscular Dystrophy, Epilepsy, Genital Warts (Condylomata Acuminata),
Human Immunodeficiency Virus (HIV) Infections (AIDS),
Keratoconjunctivitis Sicca (Dry Eye), Multiple Sclerosis, Paraneoplastic
Syndrome, Relapsing Remitting Multiple Sclerosis (RRMS), Secondary
Progressive Multiple Sclerosis (SPMS), Unspecified and Ventricular
Septal Defect.

The latest report Integrin Alpha 4 – Pipeline Review, H1 2019, outlays
comprehensive information on the Integrin Alpha 4 targeted therapeutics,
complete with analysis by indications, stage of development, mechanism
of action (MoA), route of administration (RoA) and molecule type. It
also reviews key players involved in Integrin Alpha 4 (CD49 Antigen Like
Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) targeted
therapeutics development with respective active and dormant or
discontinued projects.

Scope

• The report provides a snapshot of the global therapeutic landscape for
  Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit
  Alpha or CD49d or ITGA4)
• The report reviews Integrin Alpha 4 (CD49 Antigen Like Family Member D
  or VLA4 Subunit Alpha or CD49d or ITGA4) targeted therapeutics under
  development by companies and universities/research institutes based on
  information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of
  development ranging from pre-registration till discovery and
  undisclosed stages
• The report features descriptive drug profiles for the pipeline
  products which includes, product description, descriptive MoA, R&D
  brief, licensing and collaboration details & other developmental
  activities
• The report reviews key players involved in Integrin Alpha 4 (CD49
  Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4)
  targeted therapeutics and enlists all their major and minor projects
• The report assesses Integrin Alpha 4 (CD49 Antigen Like Family Member
  D or VLA4 Subunit Alpha or CD49d or ITGA4) targeted therapeutics based
  on mechanism of action (MoA), route of administration (RoA) and
  molecule type
• The report summarizes all the dormant and discontinued pipeline
  projects
• The report reviews latest news and deals related to Integrin Alpha 4
  (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or
  ITGA4) targeted therapeutics

Reasons to Buy

• Gain strategically significant competitor information, analysis, and
  insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio
  and create effective counter-strategies to gain competitive advantage
• Identify and understand the targeted therapy areas and indications for
  Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit
  Alpha or CD49d or ITGA4)
• Identify the use of drugs for target identification and drug
  repurposing
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of
  leading companies
• Plan mergers and acquisitions effectively by identifying key players
  and it’s most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding
  Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit
  Alpha or CD49d or ITGA4) development landscape
• Develop and design in-licensing and out-licensing strategies by
  identifying prospective partners with the most attractive projects to
  enhance and expand business potential and scope

Key Topics Covered:

1. Introduction
2. Report Coverage
3. Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit
   Alpha or CD49d or ITGA4) – Overview
4. Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit
   Alpha or CD49d or ITGA4) – Therapeutics Development
5. Products under Development by Stage of Development
6. Products under Development by Therapy Area
7. Products under Development by Indication
8. Products under Development by Companies
9. Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit
   Alpha or CD49d or ITGA4) – Therapeutics Assessment
10. Assessment by Mechanism of Action
11. Assessment by Route of Administration
12. Assessment by Molecule Type
13. Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit
    Alpha or CD49d or ITGA4) – Companies Involved in Therapeutics
    Development

• Antisense Therapeutics Ltd
• Biogen Inc
• C4X Discovery Holdings PLC
• Daiichi Sankyo Co Ltd
• EA Pharma Co Ltd
• Immunwork Inc
• Morphic Therapeutic Inc
• Protagonist Therapeutics Inc
• Takeda Pharmaceutical Co Ltd

Featured News & Press Releases

Mar 11, 2019: Takeda’s Entyvio achieves superior remission than Humira
in ulcerative colitis

Mar 11, 2019: Takeda Canada announces positive results for ENTYVIO
(vedolizumab) vs. Humira (adalimumab) in first IBD study to compare
biological agents head-to-head

Jan 29, 2019: Perrigo To Receive Milestone Payment Of $250 Million From
RPI Finance Trust

Jan 18, 2019: Antisense Therapeutics provides phase II clinical trial in
duchenne muscular dystrophy

Jan 07, 2019: RM LAW announces class action lawsuit against Perrigo
Company

Jan 03, 2019: First Patient enrolled in Biogens phase 3b Study to
evaluate Extended Interval Dosing (EID) with Natalizumab in Multiple
Sclerosis

Dec 17, 2018: Entyvio post-marketing safety data consistent with
previous clinical trials

Dec 13, 2018: Protagonist Therapeutics initiates phase 1 trial of oral,
gut-restricted, alpha-4-beta-7 integrin antagonist PN-10943

Nov 27, 2018: Protagonist Therapeutics announces new development
candidate PN-10943 for the treatment of inflammatory bowel disease

Nov 07, 2018: Takeda announces launch of Entyvio (vedolizumab) for the
treatment of adult patients with moderately to severely active
ulcerative colitis in Japan

Oct 27, 2018: Takeda comments on ongoing Phase 1 review by the European
Commission of the proposed acquisition of Shire

Oct 22, 2018: Investigational subcutaneous formulation of Vedolizumab
achieves and maintains clinical remission and mucosal healing at Week 52
in patients with moderately to severely active Ulcerative Colitis

Oct 11, 2018: Biogen to present on TYSABRI at 34th Congress of the
European Committee for Treatment and Research

Oct 08, 2018: New real-world data analyses support the long-term use of
Entyvio (Vedolizumab) in bio-nave patients for the treatment of moderate
to severe ulcerative colitis or crohn’s disease

Oct 02, 2018: Biogen announces presentation on TYSABRI at ECTRIMS 2018

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/a6b2c7

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Related
Topics: Oncology
Drugs